Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2018 · New England Journal of Medicine · 2,701 citations
https://doi.org/10.1056/nejmoa1810858
A
Anne Floquet
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
496
Papers
18.1K
Citations
52
h-index
118
i10-index
Anne Floquet is an academic researcher. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & Uterine Myomas and Treatments & PARP inhibition in cancer therapy. The author has an h-index of 52, co-authored 422 publications.
ORCID: 0000-0002-1078-8554Papers by this author
worksEfficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
2020 · Journal of Clinical Oncology · 116 citations
https://doi.org/10.1200/jco.20.00799
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
2013 · British Journal of Cancer · 102 citations
https://doi.org/10.1038/bjc.2013.183
DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
2003 · British Journal of Cancer · 101 citations
https://doi.org/10.1038/sj.bjc.6601185
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
2020 · British Journal of Cancer · 85 citations
https://doi.org/10.1038/s41416-020-01153-4
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
2021 · Gynecologic Oncology · 35 citations
https://doi.org/10.1016/j.ygyno.2021.07.016
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat